Cargando…

Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension

BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including...

Descripción completa

Detalles Bibliográficos
Autores principales: Waddingham, Mark T, Edgley, Amanda J, Astolfo, Alberto, Inagaki, Tadakatsu, Fujii, Yutaka, Du, Cheng-Kun, Zhan, Dong-Yun, Tsuchimochi, Hirotsugu, Yagi, Naoto, Kelly, Darren J, Shirai, Mikiyasu, Pearson, James T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509700/
https://www.ncbi.nlm.nih.gov/pubmed/26194354
http://dx.doi.org/10.1186/s12933-015-0256-6
_version_ 1782382067781206016
author Waddingham, Mark T
Edgley, Amanda J
Astolfo, Alberto
Inagaki, Tadakatsu
Fujii, Yutaka
Du, Cheng-Kun
Zhan, Dong-Yun
Tsuchimochi, Hirotsugu
Yagi, Naoto
Kelly, Darren J
Shirai, Mikiyasu
Pearson, James T
author_facet Waddingham, Mark T
Edgley, Amanda J
Astolfo, Alberto
Inagaki, Tadakatsu
Fujii, Yutaka
Du, Cheng-Kun
Zhan, Dong-Yun
Tsuchimochi, Hirotsugu
Yagi, Naoto
Kelly, Darren J
Shirai, Mikiyasu
Pearson, James T
author_sort Waddingham, Mark T
collection PubMed
description BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including myosin light chain 2, myosin binding protein-C (MyBP-C), troponin I (TnI) and troponin T that all have important roles in regulating CB dynamics and contractility of the myocardium. Our aim was to examine if chronic ROCK inhibition prevents impaired CB dynamics and LV dysfunction in a rat model of early diabetes, and whether these changes are associated with changes in myofilament phosphorylation state. METHODS: Seven days post-diabetes induction (65 mg/kg ip, streptozotocin), diabetic rats received the ROCK inhibitor, fasudil (10 mg/kg/day ip) or vehicle for 14 days. Rats underwent cardiac catheterization to assess LV function simultaneous with X-ray diffraction using synchrotron radiation to assess in situ CB dynamics. RESULTS: Compared to controls, diabetic rats developed mild systolic and diastolic dysfunction, which was attenuated by fasudil. End-diastolic and systolic myosin proximity to actin filaments were significantly reduced in diabetic rats (P < 0.05). In all rats there was an inverse correlation between ROCK1 expression and the extension of myosin CB in diastole, with the lowest ROCK expression in control and fasudil-treated diabetic rats. In diabetic and fasudil-treated diabetic rats changes in relative phosphorylation of TnI and MyBP-C were not significant from controls. CONCLUSIONS: Our results demonstrate a clear role for ROCK in the development of LV dysfunction and impaired CB dynamics in early DCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0256-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4509700
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45097002015-07-22 Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension Waddingham, Mark T Edgley, Amanda J Astolfo, Alberto Inagaki, Tadakatsu Fujii, Yutaka Du, Cheng-Kun Zhan, Dong-Yun Tsuchimochi, Hirotsugu Yagi, Naoto Kelly, Darren J Shirai, Mikiyasu Pearson, James T Cardiovasc Diabetol Original Investigation BACKGROUND: Impaired actin–myosin cross-bridge (CB) dynamics correlate with impaired left ventricular (LV) function in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to the development of DCM. ROCK targets several sarcomeric proteins including myosin light chain 2, myosin binding protein-C (MyBP-C), troponin I (TnI) and troponin T that all have important roles in regulating CB dynamics and contractility of the myocardium. Our aim was to examine if chronic ROCK inhibition prevents impaired CB dynamics and LV dysfunction in a rat model of early diabetes, and whether these changes are associated with changes in myofilament phosphorylation state. METHODS: Seven days post-diabetes induction (65 mg/kg ip, streptozotocin), diabetic rats received the ROCK inhibitor, fasudil (10 mg/kg/day ip) or vehicle for 14 days. Rats underwent cardiac catheterization to assess LV function simultaneous with X-ray diffraction using synchrotron radiation to assess in situ CB dynamics. RESULTS: Compared to controls, diabetic rats developed mild systolic and diastolic dysfunction, which was attenuated by fasudil. End-diastolic and systolic myosin proximity to actin filaments were significantly reduced in diabetic rats (P < 0.05). In all rats there was an inverse correlation between ROCK1 expression and the extension of myosin CB in diastole, with the lowest ROCK expression in control and fasudil-treated diabetic rats. In diabetic and fasudil-treated diabetic rats changes in relative phosphorylation of TnI and MyBP-C were not significant from controls. CONCLUSIONS: Our results demonstrate a clear role for ROCK in the development of LV dysfunction and impaired CB dynamics in early DCM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0256-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-22 /pmc/articles/PMC4509700/ /pubmed/26194354 http://dx.doi.org/10.1186/s12933-015-0256-6 Text en © Waddingham et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Waddingham, Mark T
Edgley, Amanda J
Astolfo, Alberto
Inagaki, Tadakatsu
Fujii, Yutaka
Du, Cheng-Kun
Zhan, Dong-Yun
Tsuchimochi, Hirotsugu
Yagi, Naoto
Kelly, Darren J
Shirai, Mikiyasu
Pearson, James T
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title_full Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title_fullStr Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title_full_unstemmed Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title_short Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
title_sort chronic rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509700/
https://www.ncbi.nlm.nih.gov/pubmed/26194354
http://dx.doi.org/10.1186/s12933-015-0256-6
work_keys_str_mv AT waddinghammarkt chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT edgleyamandaj chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT astolfoalberto chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT inagakitadakatsu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT fujiiyutaka chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT duchengkun chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT zhandongyun chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT tsuchimochihirotsugu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT yaginaoto chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT kellydarrenj chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT shiraimikiyasu chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension
AT pearsonjamest chronicrhokinaseinhibitionimprovesleftventricularcontractiledysfunctioninearlytype1diabetesbyincreasingmyosincrossbridgeextension